Stock Track | Hims & Hers Health Plunges 6.09% After-Hours as Novo Nordisk Threatens Legal Action Over $49 Wegovy Copycat

Stock Track

Feb 06

Hims & Hers Health Inc. (HIMS) experienced a sharp after-hours plunge of 6.09% on Thursday. The decline followed a volatile trading session where the stock initially rallied on news of a new product launch.

The sell-off was triggered after pharmaceutical giant Novo Nordisk announced plans to pursue legal and regulatory action against Hims & Hers. The legal threat came in response to Hims & Hers launching a cheaper, compounded version of Novo's blockbuster Wegovy weight-loss pill at an introductory price of $49 per month.

Novo Nordisk condemned the move as "illegal mass compounding" that poses significant risks to patient safety, stating that compounded semaglutide is not FDA-approved and may contain impurities. This created immediate market uncertainty about the legality and commercial viability of Hims & Hers' new product offering, prompting investors to sell shares in after-hours trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1138182970"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1138182970\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1138182970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 05:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138182970","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Plunges 6.09% After-Hours as Novo Nordisk Threatens Legal Action Over $49 Wegovy Copycat","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a sharp after-hours plunge of 6.09% on Thursday. The decline followed a volatile trading session where the stock initially rallied on news of a new product launch.</p><p>The sell-off was triggered after pharmaceutical giant Novo Nordisk announced plans to pursue legal and regulatory action against Hims & Hers. The legal threat came in response to Hims & Hers launching a cheaper, compounded version of Novo's blockbuster Wegovy weight-loss pill at an introductory price of $49 per month.</p><p>Novo Nordisk condemned the move as \"illegal mass compounding\" that poses significant risks to patient safety, stating that compounded semaglutide is not FDA-approved and may contain impurities. This created immediate market uncertainty about the legality and commercial viability of Hims & Hers' new product offering, prompting investors to sell shares in after-hours trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Plunges 6.09% After-Hours as Novo Nordisk Threatens Legal Action Over $49 Wegovy Copycat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Plunges 6.09% After-Hours as Novo Nordisk Threatens Legal Action Over $49 Wegovy Copycat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-06 05:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a sharp after-hours plunge of 6.09% on Thursday. The decline followed a volatile trading session where the stock initially rallied on news of a new product launch.</p><p>The sell-off was triggered after pharmaceutical giant Novo Nordisk announced plans to pursue legal and regulatory action against Hims & Hers. The legal threat came in response to Hims & Hers launching a cheaper, compounded version of Novo's blockbuster Wegovy weight-loss pill at an introductory price of $49 per month.</p><p>Novo Nordisk condemned the move as \"illegal mass compounding\" that poses significant risks to patient safety, stating that compounded semaglutide is not FDA-approved and may contain impurities. This created immediate market uncertainty about the legality and commercial viability of Hims & Hers' new product offering, prompting investors to sell shares in after-hours trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1138182970","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138182970","pubTimestamp":1770328742,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a sharp after-hours plunge of 6.09% on Thursday. The decline followed a volatile trading session where the stock initially rallied on news of a new product...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票追踪|Hims&Hers Health盘后暴跌6.09%，诺和诺德威胁对49美元Wegovy山寨产品采取法律行动","themeId":"f0fce81d99e7c4115b5691df849cabad","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a sharp after-hours plunge of 6.09% on Thursday. The decline followed a volatile trading session where the stock initially rallied on news of a new product launch.The sell-off was triggered after pharmaceutical giant Novo Nordisk announced plans to pursue legal and regulatory action against Hims & Hers. The legal threat came in response to Hims & Hers launching a cheaper, compounded version of Novo's blockbuster Wegovy weight-loss pill at an introductory price of $49 per month.Novo Nordisk condemned the move as \"illegal mass compounding\" that poses significant risks to patient safety, stating that compounded semaglutide is not FDA-approved and may contain impurities. This created immediate market uncertainty about the legality and commercial viability of Hims & Hers' new product offering, prompting investors to sell shares in after-hours trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}